Silencing IGF2BP3, a TLR4/NANOG–dependent gene, inhibits pluripotency genes and tumorigenesis and abrogates the chemoresistance of tumor-initiating cells [9]. This evidence concerns the gene IGF2BP3 and neoplasm.